Kyverna Therapeutics, Inc. Common Stock (KYTX) — Financial Flexibility Index
Kyverna Therapeutics, Inc. Common Stock (KYTX) has a Financial Flexibility Index of -0.68x as of March 2026. Free cash flow of $-41.60 Million (operating CF $-41.60 Million minus capex $0.00) represents -1% of total liabilities ($61.44 Million). Check Kyverna Therapeutics, Inc. Common Stock asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Kyverna Therapeutics, Inc. Common Stock Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for Kyverna Therapeutics, Inc. Common Stock across 5 annual periods. See KYTX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Kyverna Therapeutics, Inc. Common Stock (2021–2025)
Year-by-year free cash flow to debt coverage for Kyverna Therapeutics, Inc. Common Stock. For the full company profile including market capitalisation, see market value of Kyverna Therapeutics, Inc. Common Stock.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.50x | $-153.71 Million | $-153.71 Million | $61.55 Million | ▲ +15.2% |
| 2024 | -2.94x | $-112.05 Million | $-114.25 Million | $38.06 Million | ▼ -47.9% |
| 2023 | -1.99x | $-51.79 Million | $-52.41 Million | $26.02 Million | ▼ -14.0% |
| 2022 | -1.75x | $-35.34 Million | $-36.11 Million | $20.25 Million | ▼ -1002.2% |
| 2021 | -0.16x | $-20.87 Million | $-22.16 Million | $131.74 Million | — |